

Stressgen

VEGF Monoclonal Antibody

Product Specifications					
Catalog Number:	905-124				
Host:	Mouse				
Isotype:	IgM				
Species Reactivity:	Human				
Predicted m.w.:	~39 kDa				
Applications: <i>The optimal dilution for a specific application must be determined by the investigator</i>	WB: Yes IP: Yes EIA: 1:10,000				
Concentration:	Reconstitute with water to 1 mg/mL				
Purification:	Boric Acid precipitation				
Format:	500 µg lyophilized in PBS				
Storage:	Lyophilized: store desiccated at 4°C Liquid: store at -20°C				
Immunogen:	Recombinant human VEGF				
Related Products:	<table border="0"> <tr> <td>900-080</td> <td>Human VEGF EIA Kit</td> </tr> <tr> <td>900-164</td> <td>VEGF Monoclonal Antibody</td> </tr> </table>	900-080	Human VEGF EIA Kit	900-164	VEGF Monoclonal Antibody
900-080	Human VEGF EIA Kit				
900-164	VEGF Monoclonal Antibody				

Vascular Endothelial Growth Factor (VEGF, VEGF-165) is the predominant member of a family of endothelial cell-specific mitogens that are related by structure and function. The 165 amino acid variant is the most common soluble secreted form found in human tissues. Biologically active as a homodimer or a heterodimer with VEGF-B, this paracrine growth factor stimulates angiogenesis by specifically activating vascular endothelial cells through a MAP kinase cascade¹⁻³. VEGF is not only essential for normal vascular embryonic and reproductive angiogenesis but also is central to growth and dissemination in a number of cancerous states⁴⁻⁶. Because of these pleiotropic effects, VEGF is valued for its predictive and therapeutic target applications for a variety of pathological states including breast cancer, non-Hodgkins lymphoma, melanoma, and rheumatoid arthritis⁷⁻¹⁰.

References:

1. Carmeliet, P. and Collen, D. (2000) *Ann NY Acad Sci.* **902**, 249-262.
2. Gerwins, P., *et al.* (2000) *Crit Rev Oncol Helatol.* **34/3**, 185-194.
3. Pages, G., *et al.* (2000) *Ann NY Acad Sci.* **902**, 187-200.
4. Breier, G. (2000) *Placenta* **21 Suppl A**, 11-15.
5. Ferrara, N., *et al.* (1998) *Nat Med.* **4/3**, 336-340.
6. Carmeliet, P. and Jain, R.K. (2000) *Nature* **407**, 249-257.
7. Toi, M., *et al.* (2000) *Breast Cancer* **7/4**, 311-314.
8. Salven, P., *et al.* (2000) *Blood* **96/12**, 3712-3718.
9. Lazar-Molnar, E., *et al.* (2000) *Cytokine* **12/6**, 547-554.
10. Koch, A.E., *et al.* (1994) *J Immunol.* **152/8**, 4149-41556.